Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer
COPD 和肺癌中前列环素-PPARy 轴的共同靶向
基本信息
- 批准号:8490706
- 负责人:
- 金额:$ 56.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-15 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAgingAgonistAllyAnimal ModelAnti-CholinergicsAntioxidantsApoptoticBiological MarkersBreathingCell AgingCellsChemopreventive AgentChronicChronic BronchitisChronic Obstructive Airway DiseaseClinical TrialsDataDevelopmentDiseaseDisease ProgressionDysplasiaEnvironmental Risk FactorEtiologyExtracellular MatrixFDA approvedFailureFundingGenotoxic StressGoalsHumanIloprostImageIndividualInflammationInflammatoryInterventionIntraepithelial NeoplasiaInvestigationLeadLigandsLinkLungLung InflammationLung NeoplasmsLung diseasesMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMediator of activation proteinModelingModificationMolecularMusObstructionOrganOxidantsOxidative StressPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhase II Clinical TrialsPioglitazonePositioning AttributePremalignantProcessProstaglandins IProteolysisPulmonary EmphysemaResearchRetinoidsRiskSafetySignal TransductionSmokeSmokerStructure of parenchyma of lungSupplementationTestingTobaccoTobacco smokeVitaminsanalogbasecancer chemopreventioncancer riskdisease phenotypehigh riskinsightlung carcinogenesislung injuryneoplasticnovelpreclinical studyresearch study
项目摘要
DESCRIPTION (provided by applicant): Smokers with the overlapping COPD phenotypes of airflow obstruction, chronic bronchitis or emphysema carry a significantly higher risk of developing lung cancer, as two recent studies indicated that emphysema detected by CT imaging may be a stronger predictor of lung cancer risk than spirometric airflow obstruction. Lung inflammation and excessive extracellular matrix proteolysis have been implicated as mediators of lung injury by tobacco smoke. Furthermore, tobacco smoke-triggered oxidative stress initiates lung inflammation and progressively disrupts cellular signaling involved in maintenance of lung integrity, eventually leading to organ aging and cell senescence. There are as yet no specific treatments for tobacco smoke-induced lung diseases that target the reversal of lung tissue destruction and promote differentiation for protecting lung tissue. Our goal is to develop novel treatments that target COPD progression and lung cancer simultaneously, based on mechanistic studies of molecular pathways that protect lung tissue from the pathogenesis of both tobacco-smoke induced diseases. Our preclinical studies have documented that prostacyclin supplementation protects against tobacco smoke-induced lung diseases, including COPD and the pre-neoplastic changes observed prior to lung cancer. We hypothesize that activation of the prostacyclin - PPAR3 axis with prostacyclin analogues and PPAR3 agonists has cytoprotective effects in tobacco smoke-induced lung disease, leading to concomitant protection from lung destruction in patients with COPD and development of the transition of epithelial dysplasia to cancer. In specific aim 1, we will determine whether PPAR3 signaling enhancement has a pro-differentiation, chemopreventive effect in individuals at risk for lung cancer and decreases lung inflammation in COPD patients. In specific aim 2, we will pursue inflammation biomarkers that characterize responders versus non-responders to PPAR3 modifying therapies. In specific aim 3, we will demonstrate in murine models that PPAR3 signaling enhancing therapies (iloprost or pioglitazone) can diminish tobacco smoke-induced lung injury; thereby decreasing the occurrence of tobacco smoke-induced lung tumors. Because the drugs being studied are already FDA approved with established safety profiles, our research could yield new treatments relatively soon that target the reversal of lung tissue destruction and promote lung tissue protection for the tobacco smoke-induced lung diseases COPD and lung cancer.
描述(由申请人提供):具有气流阻塞、慢性支气管炎或肺气肿重叠 COPD 表型的吸烟者患肺癌的风险显着更高,因为最近的两项研究表明,通过 CT 成像检测到的肺气肿可能比肺活量气流阻塞更能预测肺癌风险。肺部炎症和过度的细胞外基质蛋白水解被认为是烟草烟雾造成的肺损伤的介质。此外,烟草烟雾引发的氧化应激会引发肺部炎症,并逐渐破坏参与维持肺部完整性的细胞信号传导,最终导致器官衰老和细胞衰老。目前还没有针对烟草烟雾引起的肺部疾病的具体治疗方法,以逆转肺组织破坏并促进分化以保护肺组织。我们的目标是基于对保护肺组织免受烟草烟雾诱发疾病发病机制影响的分子途径的机制研究,开发同时针对慢性阻塞性肺病进展和肺癌的新型治疗方法。我们的临床前研究证明,补充前列环素可以预防烟草烟雾诱发的肺部疾病,包括慢性阻塞性肺病和肺癌之前观察到的肿瘤前变化。我们假设,用前列环素类似物和 PPAR3 激动剂激活前列环素 - PPAR3 轴,对烟草烟雾诱发的肺部疾病具有细胞保护作用,从而导致 COPD 患者同时免受肺破坏和上皮发育不良向癌症的转变。在具体目标 1 中,我们将确定 PPAR3 信号传导增强是否对有肺癌风险的个体具有促分化和化学预防作用,并减少 COPD 患者的肺部炎症。在具体目标 2 中,我们将寻找能够表征 PPAR3 修饰疗法有反应者与无反应者特征的炎症生物标志物。在具体目标 3 中,我们将在小鼠模型中证明 PPAR3 信号增强疗法(伊洛前列素或吡格列酮)可以减轻烟草烟雾引起的肺损伤;从而减少烟草烟雾诱发的肺部肿瘤的发生。由于正在研究的药物已获得 FDA 批准并具有既定的安全性,因此我们的研究可能会相对较快地产生新的治疗方法,以逆转肺组织破坏并促进肺组织保护,以治疗烟草烟雾引起的肺病 COPD 和肺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK W GERACI其他文献
MARK W GERACI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK W GERACI', 18)}}的其他基金
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer
COPD 和肺癌中前列环素-PPARy 轴的共同靶向
- 批准号:
8320228 - 财政年份:2011
- 资助金额:
$ 56.42万 - 项目类别:
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer
COPD 和肺癌中前列环素-PPARy 轴的共同靶向
- 批准号:
8097154 - 财政年份:2011
- 资助金额:
$ 56.42万 - 项目类别:
53rd Annual Thomas L Petty Aspen Lung Conference: Systems Biology of Lung Disease
第 53 届 Thomas L Petty Aspen 肺病年度会议:肺部疾病的系统生物学
- 批准号:
8005685 - 财政年份:2010
- 资助金额:
$ 56.42万 - 项目类别:
Prostacyclin Synthase and Receptors in Pulmonary Arterial Hypertension
肺动脉高压中的前列环素合酶和受体
- 批准号:
7824361 - 财政年份:2009
- 资助金额:
$ 56.42万 - 项目类别:
Molecular Physiology Core Applied to Acute Lung Injury
分子生理学核心应用于急性肺损伤
- 批准号:
7936177 - 财政年份:2009
- 资助金额:
$ 56.42万 - 项目类别:
Molecular Physiology Core Applied to Acute Lung Injury
分子生理学核心应用于急性肺损伤
- 批准号:
7859480 - 财政年份:2009
- 资助金额:
$ 56.42万 - 项目类别:
Mechanisms of Prostacyclin signaling in Pulmonary Arterial Hypertension
肺动脉高压中前列环素信号传导机制
- 批准号:
7662797 - 财政年份:2009
- 资助金额:
$ 56.42万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Collaborative R&D
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Operating Grants
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Studentship
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Fellowship Award
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Standard Grant
McGill-MOBILHUB: Mobilization Hub for Knowledge, Education, and Artificial Intelligence/Deep Learning on Brain Health and Cognitive Impairment in Aging.
McGill-MOBILHUB:脑健康和衰老认知障碍的知识、教育和人工智能/深度学习动员中心。
- 批准号:
498278 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Operating Grants
Welfare Enhancing Fiscal and Monetary Policies for Aging Societies
促进老龄化社会福利的财政和货币政策
- 批准号:
24K04938 - 财政年份:2024
- 资助金额:
$ 56.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




